Mantle Cell Lymphoma | Specialty

The OncLive Mantle Cell Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma treatment. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, therapeutic advances, and ongoing research in mantle cell lymphoma.

Dr Cohen on Treatment Considerations for Relapsed/Refractory MCL

February 21st 2024

Jonathon B. Cohen, MD, MS, discusses treatment considerations for mantle cell lymphoma and the role of pirtobrutinib in the management of this disease.

Ibrutinib Combined With Venetoclax in Patients With Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results From the Randomized Phase 3 SYMPATICO Study

February 20th 2024

Michael Wang, MD, presents the primary analysis results from the multinational, randomized, double-blind, phase 3 SYMPATICO study comparing ibrutinib plus venetoclax vs ibrutinib plus placebo in patients with relapsed/refractory mantle cell lymphoma (R/R MCL).

Future Directions and Unmet Needs in Relapsed/Refractory MCL

February 20th 2024

A panel of experts discuss future directions and remaining unmet needs for patients with relapsed/refractory MCL.

Dr Pearse on the BOVen Trial of BTK Inhibitor Combinations in TP53-Mutant MCL

February 19th 2024

William B. Pearse, MD, discusses the significance of the ongoing phase 2 BOVen trial in TP53-mutant mantle cell lymphoma.

Bispecific Antibodies and Noncovalent BTK Inhibitors Expand Horizons in DLBCL and MCL

February 18th 2024

Catherine C. Coombs, MD, spotlights the use of bispecific antibodies in diffuse large B-cell lymphoma and pirtobrutinib in mantle cell lymphoma.

Dr Cohen on Available Treatments For MCL

February 14th 2024

Jonathon B. Cohen, MD, MS, discusses the background of the BRUIN study of pirtobrutinib in previously treated patients with mantle cell lymphoma.

Sequencing Therapies in the Third-Line and Beyond Setting for MCL

February 13th 2024

A panel of experts discuss how to sequence BTK inhibitors and CAR T-cell therapies in patients with MCL.

Current Treatment Options in Third-line MCL

February 13th 2024

Experts on mantle cell lymphoma discuss third-line treatment options available for patients.

Dr Goy on the Rationale for Launching the ZUMA-18 Trial in Relapsed/Refractory MCL

February 13th 2024

Andre Goy, MD, discusses the evaluation of brexu-cel in the ZUMA-2 and expanded access ZUMA-18 trials in relapsed/refractory mantle cell lymphoma.

Dr Pearse on Efforts to Elucidate the Optimal Sequencing of BTK Inhibitors in MCL

February 8th 2024

William B. Pearse, MD, discusses unanswered questions regarding the sequencing of pirtobrutinib and other BTK inhibitors in mantle cell lymphoma.

Current Treatment Options in Second-line MCL

February 6th 2024

Experts on mantle cell lymphoma discuss second-line treatment options available for patients.

ASH 2023 Updates on Frontline Therapies in MCL

February 6th 2024

A panel of experts review latest data from ASH 2023 on approved and emerging therapies in frontline MCL.

Pirtobrutinib Continues to Show Safety, Activity in Covalent BTK Inhibitor–Pretreated R/R MCL

February 2nd 2024

Jonathon B. Cohen, MD, MS, expands on updated data from the BRUIN trial of pirtobrutinib in patients with relapsed BTK-exposed mantle cell lymphoma.

FDA Grants Priority Review to Expand Liso-Cel Indications in R/R Follicular Lymphoma and MCL

January 30th 2024

Liso-cel sBLAs for indications in relapsed/refractory FL and MCL after exposure to a BTK inhibitor have received priority review from the FDA.

Dr Danilov on Using MRD Status to Predict Outcomes in Hematologic Malignancies

January 30th 2024

Alexey Danilov, MD, PhD, discusses the use of minimal residual disease to predict outcomes in patients with follicular lymphoma.

Current Treatment Options in First-Line MCL

January 30th 2024

Experts on mantle cell lymphoma discuss first-line treatment options available for patients.

CD19 CAR T Cells Plus Acalabrutinib Shows Early Activity in Relapsed/Refractory MCL

January 29th 2024

CD19 CAR T cell therapy plus acalabrutinib demonstrated early efficacy in patients with relapsed/refractory mantle cell lymphoma.

Dr Pearse on the Use of BTK Inhibitors in Relapsed/Refractory MCL

January 25th 2024

William B. Pearse, MD, discusses the current and future roles of BTK inhibitors in patients with relapsed/refractory mantle cell lymphoma.

Pirtobrutinib Expands MCL Armamentarium, Although Sequencing Questions Remain

January 24th 2024

William Pearse, MD, discusses how the FDA approval of pirtobrutinib for relapsed/refractory mantle cell lymphoma has advanced BTK inhibitor treatment.

BTK Inhibitor–Associated AEs Can Influence Treatment Selection in MCL

January 23rd 2024

William Pearse, MD, discusses the roles of acalabrutinib and zanubrutinib in mantle cell lymphoma, as well as the adverse effect profiles of each agent.